Survodutide

[Letits now]

Any adventurous individuals try Survodutide yet? It’s starting to pop up on peoples price lists.

 

[Sector]

Kind of interesting. Haven't heard of it until now.

Rather let other people be the test guinea pig first though.

Seems maybe slightly more effective than semaglutide, but the sides also seem to be more pronounced with 78% of the people reporting adverse sides. Personally I think tirzepatide is the king of the GLP agonists (for now).

Rather go with something with more research, studies, and human clinical trials behind it as well. Seems like survodutide is still in phase 3 clinical, or maybe recently just got out of it? I only did a brief search and brief reading into it

Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial - PubMed

Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.

pubmed.ncbi.nlm.nih.gov

"Mean (95% CI) bodyweight decreased dose-dependently up to -8.7% (-10.1, -7.3; DG6, n=37); survodutide ≥1.8 mg qw produced greater bodyweight reductions than semaglutide (-5.3% [-6.6, -4.1]; n=45). Adverse events (AEs) were reported for 77.8% of survodutide-treated participants (mainly gastrointestinal)"

 

[Letits now]

Kind of interesting. Haven't heard of it until now.

Rather let other people be the test guinea pig first though.

Seems maybe slightly more effective than semaglutide, but the sides also seem to be more pronounced with 78% of the people reporting adverse sides. Personally I think tirzepatide is the king of the GLP agonists (for now).

Rather go with something with more research, studies, and human clinical trials behind it as well. Seems like survodutide is still in phase 3 clinical, or maybe recently just got out of it? I only did a brief search and brief reading into it

Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial - PubMed

Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.

pubmed.ncbi.nlm.nih.gov

"Mean (95% CI) bodyweight decreased dose-dependently up to -8.7% (-10.1, -7.3; DG6, n=37); survodutide ≥1.8 mg qw produced greater bodyweight reductions than semaglutide (-5.3% [-6.6, -4.1]; n=45). Adverse events (AEs) were reported for 77.8% of survodutide-treated participants (mainly gastrointestinal)"

Thanks for the link. Great stuff. I want other people to try it first as well. Also agree that when both weight loss and sides are taken into account, Tirz is king. But I don’t take glp’s all the time and would like to cycle through different ones when I am to ensure I can keep dosage low. Trying to avoid getting used to the different ones (glp, gip, gcgr, amylin, etc.)

 

[Sector]

Thanks for the link. Great stuff. I want other people to try it first as well. Also agree that when both weight loss and sides are taken into account, Tirz is king. But I don’t take glp’s all the time and would like to cycle through different ones when I am to ensure I can keep dosage low. Trying to avoid getting used to the different ones (glp, gip, gcgr, amylin, etc.)

Yeah that's fair. I appreciate you bringing the topic up. It's always good to learn about the different mechanisms of action that these newer GLPs use